registHER: An observational cohort study of patients with HER2+metastatic breast cancer

被引：0

作者：

Yood, Marianne Ulcickas ^{[1
,2
]}

Kaufman, Peter A. ^{[3
,4
]}

Mayer, Musa ^{[5
]}

Rugo, Hope ^{[6
]}

Brufsky, Adam ^{[7
]}

Tan-Chiu, Elizabeth ^{[8
]}

Yardley, Denise ^{[9
]}

Paik, Soonmyung ^{[10
]}

Wang, Lisa ^{[11
]}

Birkner, Merrill ^{[11
]}

Brammer, Melissa ^{[11
]}

Tripathy, Debu ^{[12
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] EpiSource, Hamden, CT USA

[3] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[4] Norris Cotton Canc Ctr, Lebanon, NH USA

[5] AdvancedBC Org, New York, NY USA

[6] UCSF, Ctr Comprehens Canc, San Francisco, CA USA

[7] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA

[8] Florida Canc Care, Tamarac, FL USA

[9] Sarah Cannon Res Inst, Nashville, TN USA

[10] Natl Surtal Breast & Bowel Project, Pittsburgh, PA USA

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

090

引用

页码：S40 / S40

页数：1

共 50 条

[21] HEALTH STATE UTILITY VALUES FOR HER2+METASTATIC BREAST CANCER
Paracha, N.
Thuresson, P.
Ray, J.
VALUE IN HEALTH, 2017, 20 (05) : A115 - A115
[22] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
Mudumba, R.
Chan, H.
Cheng, Y. Y.
Wang, C. C.
Correia, L.
Ballreich, J.
Levy, J.
VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
[23] TREATMENT RATES IN PATIENTS WITH HER2+METASTATIC BREAST CANCER AND THE FACTORS INFLUENCING TREATMENT DECISION
Colomer, R.
Hall, P.
Szkultecka-Debek, M.
Bondi, R.
Flinois, A.
Auziere, S.
Le Cleach, J.
VALUE IN HEALTH, 2016, 19 (07) : A764 - A765
[24] Long term HER2+metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA
Spano, J. -P.
Beuzeboc, P.
Coeffic, D.
Arnould, L.
Lortholary, A.
Andre, F.
Ferrero, J. -M.
BREAST, 2015, 24 (04): : 376 - 383
[25] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
Burstein, H. J.
Keshaviah, A.
Baron, A.
Hart, R.
Lambert-Falls, R.
Marcom, P. K.
Gelman, R.
Winer, E. P.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
[26] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer
Andrieu, Charlotte
Al-Sultan, Dalal
Ivers, Laura
Pina, Jose Javier Berenguer
Skrobo, Darko
Ballot, Josephine
Eustace, Alex J.
Gullo, Giuseppe
Crown, John
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
Parsons, Heather
Ruddy, Kathryn
Morganti, Stefania
Smith, Karen
Attaya, Victoria
Kallfelz, Eliza
DeMeo, Michelle
LaScala, Jamie
Mertz, Shirley
Pollastro, Teri
Spears, Patricia
Brufsky, Adam
Dang, Chau
Dent, Susan
Elkhanany, Ahmed
Gwin, WIlliam
O'Sullivan, Ciara
Miller, Kathy
Nunnery, Sara
Walsh, Elaine
Storniolo, Anna Maria
Tolaney, Sara
Tayob, Nabihah
Wolff, Antonio
Winer, Eric
Rimawi, Mothaffar
Krop, Ian
Lin, Nancy
CANCER RESEARCH, 2024, 84 (09)
[28] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
Pegram, Mark
Pietras, Richard
Dang, Chau T.
Murthy, Rashmi
Bachelot, Thomas
Janni, Wolfgang
Sharma, Priyanka
Hamilton, Erika
Saura, Cristina
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[29] The role of tyrosine kinase inhibitors in the treatment of HER2+metastatic breast cancer
Le Du, Fanny
Dieras, Veronqiue
Curigliano, Giuseppe
EUROPEAN JOURNAL OF CANCER, 2021, 154 : 175 - 189
[30] Effectiveness of Trastuzumab in First-Line HER2+Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study
Negri, Eva
Zambelli, Alberto
Franchi, Matteo
Rossi, Marta
Bonifazi, Martina
Corrao, Giovanni
Moja, Lorenzo
Zocchetti, Carlo
La Vecchia, Carlo
ONCOLOGIST, 2014, 19 (12): : 1209 - 1215

← 1 2 3 4 5 →